Brokers

Brokers Set Expectations for Hookipa Pharma Inc’s FY2028 Earnings (NASDAQ:HOOK)


Hookipa Pharma Inc (NASDAQ:HOOKFree Report) – Equities researchers at HC Wainwright issued their FY2028 earnings per share estimates for shares of Hookipa Pharma in a report released on Monday, March 25th. HC Wainwright analyst A. He forecasts that the company will post earnings of $0.31 per share for the year. HC Wainwright currently has a “Buy” rating and a $6.50 target price on the stock. The consensus estimate for Hookipa Pharma’s current full-year earnings is ($0.60) per share.

Separately, Royal Bank of Canada reissued an “outperform” rating and issued a $5.00 target price on shares of Hookipa Pharma in a research report on Monday.

Check Out Our Latest Stock Analysis on Hookipa Pharma

Hookipa Pharma Price Performance

HOOK opened at $0.72 on Tuesday. The stock has a 50-day moving average price of $0.70 and a 200-day moving average price of $0.63. The firm has a market cap of $60.36 million, a PE ratio of -0.82 and a beta of 1.03. Hookipa Pharma has a 1 year low of $0.41 and a 1 year high of $2.05.

Hedge Funds Weigh In On Hookipa Pharma

A number of hedge funds have recently bought and sold shares of the business. Bank of America Corp DE raised its position in Hookipa Pharma by 1.2% in the 1st quarter. Bank of America Corp DE now owns 429,535 shares of the company’s stock worth $316,000 after buying an additional 5,199 shares during the last quarter. State Street Corp grew its stake in shares of Hookipa Pharma by 18.5% during the 2nd quarter. State Street Corp now owns 169,174 shares of the company’s stock valued at $149,000 after purchasing an additional 26,367 shares during the period. Royal Bank of Canada grew its stake in shares of Hookipa Pharma by 10.8% during the 3rd quarter. Royal Bank of Canada now owns 290,956 shares of the company’s stock valued at $390,000 after purchasing an additional 28,263 shares during the period. Virtu Financial LLC bought a new stake in shares of Hookipa Pharma during the 2nd quarter valued at about $47,000. Finally, Mirabella Financial Services LLP bought a new stake in shares of Hookipa Pharma during the 1st quarter valued at about $82,000. Hedge funds and other institutional investors own 83.02% of the company’s stock.

About Hookipa Pharma

(Get Free Report)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

See Also

Earnings History and Estimates for Hookipa Pharma (NASDAQ:HOOK)



Receive News & Ratings for Hookipa Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hookipa Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.


    Input this code: captcha